Related Experiment Videos
Clinical perspective on celiprolol: cardioprotective potential
1Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10461.
Insights
Beta-blockers protect heart attack survivors by preventing plaque rupture and reducing blood clots, not through direct blood thinning. This mechanism helps lower mortality and reinfarction risks.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-adrenergic blockers are widely used for cardiovascular disease.
- They reduce mortality, sudden death, and reinfarction in acute myocardial infarction survivors.
- The exact cardioprotective mechanism remains unclear.
Purpose of the Study:
- To explore the antithrombotic mechanisms of beta-blockers.
- To investigate how beta-blockers may prevent coronary artery plaque rupture.
- To highlight the potential benefits of celiprolol.
Main Methods:
- Review of existing literature on beta-blocker mechanisms.
- Analysis of proposed antithrombotic and hemodynamic effects.
- Comparison of celiprolol's properties with other beta-blockers.
Main Results:
- Beta-blockers may exert antithrombotic effects by preventing plaque rupture and thrombus propagation.
- Hemodynamic stabilization by beta-blockers may protect vulnerable plaques.
- Celiprolol offers additional benefits, including not affecting lipids, preserving myocardial function, lowering fibrinogen, and reducing left ventricular hypertrophy.
Conclusions:
- Beta-blockers' cardioprotective effects likely involve preventing coronary plaque rupture and thrombosis.
- Celiprolol demonstrates favorable properties beyond standard beta-blocker activity.
- Further research into these mechanisms could optimize cardiovascular disease treatment.
Abstract:
beta-Adrenergic blockers have had widespread use in the treatment of cardiovascular disease. Some agents of this class have been shown to reduce the incidence of total mortality, cardiovascular mortality, sudden death, and nonfatal reinfarction in survivors of acute myocardial infarction. The mechanism for this cardioprotective action is not known. Antiarrhythmic action and hemodynamic alterations have been suggested as possible mechanisms. An anticoagulant mechanism is another possibility, although the antiplatelet effects of beta-blockers are weak. It is now believed that antithrombotic effects may be related to the prevention of coronary artery plaque rupture and the subsequent propagation of an occlusive arterial thrombus rather than a direct anticoagulant action. The therapeutic ability beta-blockers to attenuate the hemodynamic consequences of catecholamine surgers, as they do in aortic dissection, may protect a vulnerable plaque from fracture, reducing the risk of coronary thrombosis, myocardial infarction, and death. Celiprolol, a third-generation beta 1-selective adrenergic blocker with partial beta 2-agonist activity, is comparable to other beta-blockers in antihypertensive and antianginal activity. It has additional actions that may be beneficial to patients: (1) it does not adversely affect lipids and lipoproteins; (2) it does not appear to depress the myocardium in patients with left ventricular dysfunction; (3) it can lower serum fibrinogen levels; and (4) it can cause regression of myocardial mass in patients with left ventricular hypertrophy.